-
-
-
-
-
-
-
Diplomat Pharmacy (DPLO) Misses Q1 EPS by 26c, Revenues Beat; Offers FY19 EPS Views Below Consensus, FY19 Revenue Mid-Point Guidance Above Consensus
-
-
-
-
-
-
-
Diplomat Pharmacy (DPLO) PT Lowered to $8 at Mizuho Securities
-
-
-
-
-
-
-
New Research Coverage Highlights Harmonic, ScanSource, Clean Energy Fuels, American Software, Diplomat Pharmacy, and Quidel — Consolidated Revenues, Company Growth, and Expectations for 2018
-
-
-
-
-
-
-
Diplomat Pharmacy (DPLO) Misses Q1 EPS by 2c, Beats on Revenues
-
-
-
-
-
-
-
Diplomat Initiates CEO Transition; Reaffirms 2017 Guidance and Provides Preliminary 2018 Outlook
-
-
-
-
-
-
-
Diplomat Pharmacy (DPLO) Tops Q3 EPS by 10c, Miss on Revenues; FY17 EPS Guidance Above Consensus
-
-
-
-
-
-
-
Mizuho Securities Remains Sidelined on Diplomat Pharmacy (DPLO) Following 4Q
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

